Drug Profile
Congestive heart failure-cell therapy - Angiogene
Alternative Names: AngioCell™; EPAS1-modified myoblast cell therapyLatest Information Update: 10 Nov 2006
Price :
$50
*
At a glance
- Originator Angiogene Inc
- Class
- Mechanism of Action Angiogenesis inducing agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 10 Nov 2006 No development reported - Preclinical for Congestive heart failure in Canada (unspecified route)
- 18 Jun 2003 EPAS1 gene/cell therapy is available for licensing (www.angiogene.com)
- 17 Jun 2003 Preclinical trials in Congestive heart failure in Canada (unspecified route)